BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 35748773)

  • 1. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of POC1A in lung adenocarcinoma promotes tumour progression and predicts poor prognosis.
    Li ZH; Li JY; Wu ZT; Zhu YJ; Zhuo T; Nong JS; Qian J; Peng HJ; Dai L; Wang YY; Chen MW; Zeng XC
    J Cell Mol Med; 2024 Mar; 28(6):e18135. PubMed ID: 38429900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
    Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
    Front Immunol; 2021; 12():812713. PubMed ID: 35069601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
    Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
    Wang Y; Gong H; Cao Y
    Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
    Zhong A; Chen T; Xing Y; Pan X; Shi M
    Front Immunol; 2021; 12():758648. PubMed ID: 34745134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer.
    Cui G; Wang C; Lin Z; Feng X; Wei M; Miao Z; Sun Z; Wei F
    Bioengineered; 2021 Dec; 12(1):4828-4840. PubMed ID: 34346294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RecQ mediated genome instability 2 (
    Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
    Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
    Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
    Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Analysis of
    Liu J; Zhu B; Chen J; Cao Y
    Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of
    Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
    Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
    Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
    Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
    Huang Y; You M; Wu Q; Zhu W; Guo F; Lin W
    Ann Clin Lab Sci; 2022 Nov; 52(6):904-917. PubMed ID: 36564070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.